• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Best Method for CMV Prevention in High-risk Kidney Transplant Recipients? Either, per National Norwegian Transplant Database: Commentary on Blom et al, Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.

作者信息

Kotton Camille Nelson

机构信息

Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Boston, MA.

Harvard Medical School, Boston, MA.

出版信息

Transplantation. 2023 Aug 1;107(8):1671-1672. doi: 10.1097/TP.0000000000004616. Epub 2023 May 22.

DOI:10.1097/TP.0000000000004616
PMID:37211634
Abstract
摘要

相似文献

1
The Best Method for CMV Prevention in High-risk Kidney Transplant Recipients? Either, per National Norwegian Transplant Database: Commentary on Blom et al, Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.高危肾移植受者中巨细胞病毒预防的最佳方法是什么？根据挪威国家移植数据库：对布洛姆等人《巨细胞病毒高危肾移植受者在抢先治疗与预防性治疗后的长期结局无差异》一文的评论
Transplantation. 2023 Aug 1;107(8):1671-1672. doi: 10.1097/TP.0000000000004616. Epub 2023 May 22.
2
Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.巨细胞病毒高危肾移植受者在抢先治疗与预防治疗后长期结局无差异。
Transplantation. 2023 Aug 1;107(8):1846-1853. doi: 10.1097/TP.0000000000004615. Epub 2023 Jul 20.
3
Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.监测肾移植受者巨细胞病毒特异性免疫的诊断效用：QuantiFERON-cytomegalovirus assay。
BMC Infect Dis. 2018 Apr 16;18(1):179. doi: 10.1186/s12879-018-3075-z.
4
Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. preemptive 与序贯预防性-抢先治疗方案在肾移植中治疗巨细胞病毒：治疗失败和抗病毒耐药的比较。
Transplantation. 2010 Feb 15;89(3):320-6. doi: 10.1097/TP.0b013e3181bc0301.
5
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.抢先治疗与抗病毒预防对供体血清阳性受者血清阴性肝移植患者巨细胞病毒病的影响：一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138.
6
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.预防性与抢先性口服缬更昔洛韦治疗成人肾移植受者巨细胞病毒感染的比较
Am J Transplant. 2006 Sep;6(9):2134-43. doi: 10.1111/j.1600-6143.2006.01413.x. Epub 2006 Jun 19.
7
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.伐昔洛韦预防与抢先使用缬更昔洛韦治疗预防肾移植后巨细胞病毒病
Am J Transplant. 2008 Jan;8(1):69-77. doi: 10.1111/j.1600-6143.2007.02031.x. Epub 2007 Oct 31.
8
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.伐昔洛韦预防与抢先治疗在巨细胞病毒阳性肾移植受者中的应用：一项随机临床试验的 1 年结果。
Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.
9
Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.接受缬更昔洛韦预防治疗的高危肝移植受者与接受更昔洛韦预防治疗的高危肝移植受者相比，巨细胞病毒感染发生率增加。
Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.
10
The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.尽管进行了六个月的缬更昔洛韦预防治疗，巨细胞病毒感染的负担在高危肾移植受者中仍然很高。
Transpl Infect Dis. 2021 Aug;23(4):e13577. doi: 10.1111/tid.13577. Epub 2021 Feb 18.